HIGH

Zydus Lifesciences Entecavir 0.5 mg Tablets Recalled Nationwide for Impurity Degradation Failures (D

Zydus Pharmaceuticals USA Inc. recalls 4,344 bottles of Entecavir tablets nationwide over impurity/degradation specification failures. The product, Entecavir Tablets, 0.5 mg, carries NDC 68382-920-06 and Lot E309376 with Exp 11/30/2025. The recall is active as of Sept. 24, 2025.

Quick Facts at a Glance

Recall Date
September 4, 2025
Hazard Level
HIGH
Brands
Zydus Lifesciences Ltd., Zydus Pharmaceuticals USA Inc., Entecavir
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, PREGNANT

Hazard Information

Failed Impurity/Degradation Specifications

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: N/A

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Entecavir is an antiviral medication used to treat hepatitis B. The 0.5 mg tablet is intended for adult patients requiring chronic hepatitis B management.

Why This Is Dangerous

The recall is due to impurities and potential degradation products that may affect safety and efficacy.

Industry Context

This recall is not part of a broader industry pattern

Real-World Impact

Immediate stop-use is advised. Patients should consult healthcare providers for guidance and potential switch to alternative therapies.

Practical Guidance

How to identify if yours is affected

  1. Verify NDC 68382-920-06 on the bottle label.
  2. Check Lot E309376 and Exp 11/30/2025.
  3. Confirm bottle count matches 30 tablets per bottle and total quantity 4,344 bottles.

Where to find product info

FDA recall page D-0656-2025; Zydus Pharmaceuticals USA Inc.

What timeline to expect

Refunds or replacements procedures are determined by the distributor and manufacturer; notice will be provided by official channels.

If the manufacturer is unresponsive

  • Document all contacts, call the company again, and contact the FDA for escalation.
  • File a consumer complaint with the FDA if needed.

How to prevent similar issues

  • When buying prescription medications, verify the NDC and batch details.
  • Avoid counterfeit sources; rely on licensed distributors.
  • Consult healthcare providers before switching medications.

Documentation advice

Keep bottle labels, recall notices, and all correspondence with the manufacturer for records.

Product Details

Product: Entecavir Tablets, USP 0.5 mg, 30 tablets per bottle. Manufacturer: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 68382-920-06. Lot: E309376. Exp: 11/30/2025. Quantity: 4344 bottles. Distribution: Nationwide in the United States.

Reported Incidents

No injuries or incidents are documented in the recall notice.

Key Facts

  • 4344 bottles recalled
  • NDC 68382-920-06
  • Lot E309376
  • Expiration 11/30/2025
  • Active recall as of 2025-09-04
  • Nationwide distribution in the U.S.

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPREGNANTPETS
Injury Types
POISONINGELECTRICAL

Product Details

Model Numbers
Lot E309376
Exp 11/30/2025
UPC Codes
68382-920
68382-921
68382-920-06
+9 more
Affected States
ALL
Report Date
September 24, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more